PubMed Health⌕ Search

Biomedical subjects

I Puşcaş

Publications and source records attributed to I Puşcaş.

At least 37 records · Page 2Linked to original sources
PubMedDate not supplied

Treatment of gastroduodenal ulcer by "Ulcosilvanil".

"Ulcosilvanil" (Romanian registered mark), administered in duodenal and gastric ulcer patients, leads to a constant and long-lasting inhibition of gastric acid secretion, consequently to disappearance of subjective symptoms as well as to radiologically and endoscopically proved healing of the crater. The high percentage and the quick ulcer healing by "Ulcosilvanil", as compared with antacid and anticholinergic therapy or with H2-receptor blocking agents, prove the outstanding therapeutical value of the former.

Acetazolamide↗
PubMedDate not supplied

"Ulcosilvanil"--an inhibitor of carbonic anhydrase--associated with adrenergic beta-blockers in the treatment of duodenal ulcers.

Knowing the in vivo inhibitory effect of the beta-adrenoreceptor antagonists on gastric mucosa carbonic anhydrase and the high clinical efficacy of "Ulcosilvanil" in the healing of gastric and duodenal ulcers, the authors combined propranolol with smaller doses of "Ulcosilvanil" in 925 active duodenal ulcer patients, divided into four groups. The first 236 patients were treated with small doses of "Ulcosilvanil" (20 mg/kg b.w./day active substance), the second group (of 258 cases) with high doses (35 mg/kg b.w./day) of "Ulcosilvanil", the third one (182 subjects) with propranolol only (60 mg/day) and the fourth group (349 patients) with small doses of "Ulcosilvanil" associated with 60 mg/day propranolol. Pain disappeared in all the cases of groups 1,2 and 4 after 3-6 days of treatment and in 40% of the third group. Basal acid output decreased, after 10 days of treatment, from 6.15 +/- 1.57 to 1.94 +/- 0.66 mEq/h in the first group (p less than 0.001), from 7.98 +/- 2.34 to 0.01 +/- 0.01 mEq/h in the second group (p less than 0.001), from 6.43 +/- 2.45 to 2.09 +/- 0.50 mEq/h in the third group (p less than 0.02) and from 6.76 +/- 2.80 to 0.011 +/- 0.01 mEq/h in the fourth group (p less than 0.001). Endoscopic healing was achieved, after 14 days of treatment, respectively in 78.5%, 92.4%, 51.6% and 88.41%; this percentages increased to 82.3%, 96.8%, 68.1% and 93.5% after 21 day of treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Acetazolamide↗